利拉鲁肽对2型糖尿病非酒精性脂肪肝病小鼠的作用研究
2018-12-22邢冬杰宿世震陈桂玉张彩坤宋桂红刘晓庆
邢冬杰 宿世震 陈桂玉 张彩坤 宋桂红 刘晓庆
[摘要]目的 探討利拉鲁肽对2型糖尿病非酒精性脂肪肝病的保护作用及机制。方法 选取50只小鼠,随机分为正常对照组(15只)和高糖高脂饲料组(35只),采用高糖高脂饲料联合小剂量链脲佐菌素的方法,建立2型糖尿病非酒精性脂肪肝病的小鼠模型,经处理分为正常对照组、模型对照组、利拉鲁肽组,每组10只。利拉鲁肽皮下注射8周,观察各组空腹血糖(FBG)、丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)活性、胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)及肝指数等指标;检测肝组织超氧化物歧化酶(SOD)、丙二醛(MDA)、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)的水平;采用HE染色及油红“O”染色观察肝组织病理改变;采用免疫组织化学法检测肝组织中B淋巴细胞瘤-2(Bcl-2)、Bcl-2相关X蛋白(BaX)的表达。结果 与正常对照组比较,模型对照组大鼠的FBG、FINS、HOMA-IR增高,血清TG、TC、ALT、AST含量升高,肝指数增高,肝组织中SOD活性降低、MDA含量升高、TNF-α及IL-8水平上升,HE染色、油红“O”染色肝组织中脂肪性变明显,Bcl-2蛋白表达明显减少,BaX蛋白表达明显增加(P<0.01,P<0.05)。与模型对照组比较,利拉鲁肽组的FBG、TG、TC、ALT、AST含量降低,HOMA-IR及肝指数下降;肝组织中SOD活性升高,MDA含量及TNF-α、IL-8水平下降(P<0.01);HE染色、油红“O”染色肝组织中脂肪性变明显减轻,Bcl-2蛋白表达明显增加,BaX蛋白表达明显降低(P<0.01)。结论 利拉鲁肽对2型糖尿病非酒精性脂肪肝病的小鼠肝脏具有保护作用,其机制可能与其抗氧化作用、减少炎症因子的表达及调节凋亡相关蛋白Bcl-2、BaX的表达有关。
[关键词]2型糖尿病;非酒精性脂肪肝病;利拉鲁肽;B淋巴细胞瘤-2;Bcl-2相关X蛋白
[中图分类号] R587.1 [文献标识码] A [文章编号] 1674-4721(2018)11(c)-0012-05
[Abstract] Objective To explore the protective effect and mechanism of Liraglutide on non-alcoholic fatty liver disease in mice with type 2 diabetes mellitus. Methods A total of 50 mice were selected and randomly divided into normal control group (n=15) and high-suger and high-fat diet group (n=35). A non-alcoholic fatty liver disease model of type 2 diabetes mellitus by high-sugar and high-fat diet combined with low-dose streptozotocin was established. The mice were divided into the normal control group, the model control group, and the liraglutide group after treatment, with 10 cases in each group. Liraglutide was injected subcutaneously for 8 weeks. Fast blood glucose (FBG), alanine aminotransferase (ALT) and aspartate aminotransferase (AST), insulin (FINS), insulin resistance index (HOMA-IR) and liver index were observed in each group. The level of SOD, MDA, TNF-α, IL-8 in liver tissue were detected. HE staining and oil red “O” staining were used to observe the pathological changes of liver tissue. Immunohistochemistry was used to detect the expression of B-lymphoma-2 (Bcl-2) and Bcl-2 related X-protein (BaX) in liver tissue. Results Compared with the normal control group,the level of FBG, FINS and HOMA-IR in model control group increased, the level of serum TG, TC, ALT, AST content increased, the level of liver index increased, SOD activity decreased, MDA content increased, TNF-α and IL-8 levels increased, HE staining and oil red “O” staining in liver tissue fatty change was obvious, Bcl-2 protein expression significantly decreased, and BaX protein expression increased significantly (P<0.01, P<0.05). Compared with the model control group, the contents of FBG, TG, TC, ALT, AST, HOMA-IR and liver index decreased, SOD activity increased, MDA content, TNF-α and IL-8 decreased in the Liraglutide group (P<0.01). HE staining and oil red “O” staining significantly reduced fatty degeneration, the expression of Bcl-2 protein significantly increased and the expression of BaX protein significantly decreased (P<0.01). Conclusion Liraglutide has protective effects on the liver of non-alcoholic fatty liver disease in mice with type 2 diabetes. The mechanism may be related to anti-oxidation, reducing the expression of inflammatory factors and regulating the expression of apoptosis-related proteins Bcl-2 and BaX.
[Key words] Type 2 diabetes; Non-alcoholic fatty liver disease; Liraglutide; B-cell lymphoma-2; Bcl-2 associated X protein
近年来,糖尿病非酒精性脂肪肝病(non-alcoholic fatty liver disease,NAFLD)的发病率日益升高,据统计,2型糖尿病(type 2 diabetes,T2DM)的NAFLD发病率达34%~74%,特别是伴有肥胖的T2DM,NAFLD发病率几乎为100%[1-2],因此,明确T2DM合并NAFLD的发病机制以及寻求有效的药物,对防治T2DM合并NAFLD具有重要意义。利拉鲁肽是胰高血糖素样肽-1受体激动剂类药物,具有降低血糖、血脂、减轻体重、改善胰岛素抵抗等作用[3-4],其作为新的降糖药物已广泛应用于T2DM的临床治疗。……
